Clinical Trial Update: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy [Phase 2]

View source ↗

Summary

Phase II trials are evaluating letermovir prophylaxis in relapsed/refractory multiple myeloma patients receiving elranatamab, with recruitment currently ongoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• PREVYMIS (letermovir)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Relapsed Refractory Multiple Myeloma (RRMM) | Phase 2 | Status: RECRUITING